Table 1.

Baseline characteristics of the total and the study population

	Total cohort		Final study cohort
	n	%	n	%
Total	1147	100	849	100
Age (range), y	(32-89)		(32-89)
<55	239	20.8	169	19.91
55-64	279	24.3	205	24.15
65-74	402	35.1	300	35.34
>74	227	19.8	175	20.61
Sex
Male	618	53.9	516	60.78
Female	529	46.1	333	39.22
Primary diagnosis
Breast	449	39.2	261	30.74
Prostate	266	23.2	199	23.44
Lung	281	24.5	257	30.27
Other	151	13.2	132	15.55
Treatment arm
6 × 4 Gy	571	49.8	430	50.65
1 × 8 Gy	576	50.2	419	49.35
Performance status
WHO 3-4	170	14.8	155	18.26
WHO 2	436	38.0	359	42.29
WHO 0-1	504	43.9	317	37.34
Unknown	37	3.2	18	2.12
Baseline pain score
2	16	1.4	7	0.82
3	40	3.5	29	3.42
4	71	6.2	47	5.54
5	131	11.4	91	10.72
6	125	10.9	87	10.25
7	180	15.7	137	16.14
8	330	28.8	257	30.27
9	134	11.7	104	12.25
10	117	10.2	88	10.37
Unknown	3	0.3	2	0.24
Baseline analgesia
None	145	12.6	86	10.13
Simple	415	36.2	276	32.51
Weak opioids	214	18.7	157	18.49
Strong opioids	306	26.7	273	32.16
Unknown	67	5.8	57	6.71